|Jazz Pharmaceuticals Public Limited Company -- Germany Stock|| |
EUR 121.00 3.00 2.42%
Chairman of the Board, CEO
Mr. Bruce C. Cozadd is a Chairman of the Board, Chief Executive Officer of Jazz Pharmaceuticals PLC. He has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012. He cofounded Jazz Pharmaceuticals, Inc. and has served as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.s Executive Chairman and as a member of its board of directors. From 1991 until 2001, he held various positions with ALZA Corporationrationration, a pharmaceutical company acquired by Johnson Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporationrationration, he held the roles of Chief Financial Officer and Vice President, Corporationrationrate Planning and Analysis. He serves on the boards of directors and compensation committees of Cerus Corporationrationration, a biomedical products company, and Threshold Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, and on the boards of The Nueva School, a nonprofit organization, and SFJAZZ, a nonprofit organization. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. As our Chief Executive Officer, he brings to our board of directors a detailed knowledge of our business.
Age: 52 Chairman Since 2009 MBA
353 1 634 7800 http://www.jazzpharma.com
Bruce Cozadd Latest Insider Activity
The company has return on total asset (ROA)
of 8.05 %
which means that it generated profit of $8.05 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 17.79 %
meaning that it generated $17.79 on every $100 dollars invested by stockholders.
The company has accumulated 1.58 B in total debt with debt to equity ratio (D/E) of 63.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Jazz Pharmaceuticals Public Limited Company has Current Ratio of 3.04 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinsons disease Vyxeos for high-risk acute myeloid leukemia and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. Jazz Pharmaceuticals is traded on Frankfurt Stock Exchange in Germany.Jazz Pharmaceuticals Public Limited Company (J7Z) is traded on Frankfurt Stock Exchange in Germany. It is located in Connaught House and employs 1,140 people.